Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Jaypirca is making waves in the fight against B-cell malignancies
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
It is developing the drug candidate to potentially treat immunological diseases
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Subscribe To Our Newsletter & Stay Updated
